Lanreotide Autogel® in acromegaly: a guide to its use in the EU

    loading  Checking for direct PDF access through Ovid

Abstract

Subcutaneous lanreotide Autogel® (Somatuline® Autogel®; Somatuline® Depot), a somatostatin analogue, is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. Clinical data in these patient populations indicates that recommended dosages (60-120 mg once every 4-8 weeks) of lanreotide Autogel® provides effective control of biochemical parameters, improves clinical symptoms and health-related quality of life, reduces tumour volume and is generally well tolerated.

Related Topics

    loading  Loading Related Articles